Kura Oncology stock had its Relative Strength (RS) Rating upgraded from 85 to 91 Monday.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's proprietary rating identifies price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners often have an RS Rating of above 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
Is Kura Oncology Stock A Buy?
Kura Oncology stock is currently trading above its 200-day moving average, but just below its 50-day line. While it's not currently an ideal time to jump in, see if the biotech stock goes on to offer and clear a proper buy point. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
In terms of fundamental health, the biotech firm has posted four quarters of accelerating earnings growth. Sales growth has been a different story, coming in at 0% in the latest report.
Kura Oncology stock earns the No. 181 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls, Catalyst Pharma and Dynavax Technologies are among the top 5 highly rated stocks within the group. For industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
